Theriva Biologics, Inc. — Filing Summary
Issuer and period note: The supplied filing is Synthetic Biologics, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, not a filing under the name Theriva Biologics. The company described itself as a clinical-stage microbiome therapeutics developer.
Business context and reporting period
The filing covers fiscal 2016 and includes comparative annual results for 2015 and 2014. Its lead programs were SYN-010 for IBS-C and SYN-004 (ribaxamase) to protect the gut microbiome during IV beta-lactam antibiotic treatment. Other programs were earlier-stage pertussis, PKU, and intestinal alkaline phosphatase candidates. The company reported no revenue for 2014–2016.
Key financial metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $39.3 million | $41.0 million |
| Operating loss | $39.3 million | $41.0 million |
| Net loss | $27.8 million | $44.8 million |
| Net loss per share | $0.29 | $0.54 |
| Cash used in operations | $27.9 million | $38.9 million |
| Cash and cash equivalents, year-end | $19.1 million | $20.8 million |
| Working capital, year-end | $1.8 million | $14.8 million |
| Total assets, year-end | $22.5 million | $30.8 million |
| Total liabilities, year-end | $20.2 million | $15.8 million |
| Stockholders’ equity, year-end | $2.2 million | $15.0 million |
There was no conventional interest-bearing debt amount identified in the supplied filing text. Current liabilities included $14.8 million of warrant liabilities, measured at fair value. Operating margin is not meaningful because the company had no revenue. The 2016 net loss included $11.4 million of noncash income from changes in warrant fair value; without this accounting benefit, the reported net loss would have been higher.
For Q4 2016, operating loss was $10.2 million and net loss was $2.5 million, compared with operating loss of $11.4 million and net loss of $11.3 million in Q4 2015.
Material changes versus prior periods
- Net loss narrowed by about $17.0 million in 2016, largely reflecting the favorable noncash warrant revaluation versus a warrant revaluation expense in 2015. Operating expenses declined 4%.
- Research and development expense fell 13% to $29.1 million; lower spending on IBS-C and pertussis programs partly offset higher C. difficile program and manufacturing costs. General and administrative expense rose 26% to $10.1 million.
- Cash used in operations decreased to $27.9 million from $38.9 million. Cash fell by $1.8 million during 2016, while working capital contracted substantially.
- In November 2016, the company raised approximately $23.3 million net through an offering of 25 million common shares and warrants for up to 50 million additional shares. It also sold 900,628 shares under an at-the-market agreement for approximately $1.55 million gross during 2016.
Outlook, commentary, risks, and unusual items
- Funding and going concern: Management stated that year-end cash was insufficient for its near-term plans and that additional capital was required. The auditor’s report included a going-concern explanatory paragraph citing recurring losses and substantial doubt about the company’s ability to continue without additional capital. Management warned that failure to raise funds could delay planned trials or curtail development.
- Clinical plans: The company planned to start a Phase 2b/3 adaptive pivotal study of SYN-010 in 2017, designed for approximately 840 participants. It expected to pursue SYN-004 Phase 3 trials in the first half of 2018 or later, subject to further analysis, regulatory discussions, and funding.
- Post-year-end clinical update: In January 2017, the company reported preliminary Phase 2b SYN-004 results: 2 confirmed CDI cases in the treatment group versus 7 in placebo, a reported 71.4% relative risk reduction (p=0.045). It also reported reduced new VRE colonization (p=0.0002); the reduction in all-cause antibiotic-associated diarrhea was a nonsignificant trend (p=0.13). Results were preliminary and further analyses were ongoing.
- Financing and dilution: The November 2016 offering created substantial potential dilution through warrants, with 50 million warrants issued. An additional at-the-market facility allowed sales of up to $40 million, subject to its terms. The company warned of future financing needs and possible dilution or restrictive debt terms.
- Listing and liquidity risk: Year-end stockholders’ equity of $2.3 million was below the filing’s cited NYSE MKT $6.0 million threshold for companies with recent losses, creating a risk to continued listing despite other market-capitalization criteria being met.
- Development and operating risks: Product candidates remained subject to clinical, regulatory, manufacturing, financing, intellectual-property, competition, reimbursement, and patient-enrollment uncertainties. The company relied on third-party manufacturers, generally with only one manufacturer for each lead candidate.
- Unusual accounting item: Warrant liabilities were remeasured using Level 3 valuation assumptions. The related 2016 noncash income materially improved reported net loss; the warrant liability was $14.8 million at year-end.
Important facts for investors to verify
- Confirm the issuer identity: this is a Synthetic Biologics, Inc. filing; the requested Theriva Biologics name does not match the filing.
- Review subsequent financing, cash runway, and whether funding was obtained to support the planned clinical programs.
- Check complete SYN-004 Phase 2b data and later regulatory feedback, including whether the preliminary CDI and VRE findings were confirmed.
- Verify whether the planned SYN-010 pivotal study and SYN-004 Phase 3 trials began on the stated timelines and on adequate funding.
- Assess potential dilution from outstanding warrants, options, and the at-the-market offering facility, and monitor NYSE MKT listing compliance.
- Reconcile the warrant-liability fair-value changes and their effect on reported earnings versus cash flows.